Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Medpace Holdings heads into its October 19 earnings with analyst sentiment firming while the CEO's open-market selling runs uninterrupted, a divergence that has widened since the last note.
The Street moved clearly in Medpace's favour this week. Mizuho's Ann Hynes lifted her price target to $700 from $665, maintaining Outperform, and Barclays raised its target to $625 from $600 while holding Equal-Weight. Both actions landed on October 7, within days of UBS upgrading the stock to Neutral from Sell on September 30, a more significant directional shift, with Kevin Caliendo's target jumping to $673 from $405. The consensus mean target now sits at roughly $592, modestly below the current price of $603, but the distribution is skewed: Mizuho and RBC (target $692) sit well above, while TD Cowen holds at $492. The bull case rests on recovering RFP volumes, improving win rates, and a pre-backlog pipeline that management says has been growing faster than backlog and feeds bookings with a roughly three-quarter lag. The bear case points to biopharma funding cycle exposure, regulatory delays, and the risk that elevated pass-through assumptions above 42% for the full year prove optimistic if cancellations tick up.
Valuation is not stretched by historical norms but not cheap. The P/E sits at 31.8x with the EV/EBITDA at 24.8x, both down modestly over the past 30 days as the stock pulled back 3% on the week to $603. EPS momentum scores are middling, ranking in the 56th and 63rd percentiles on 30-day and 90-day horizons. Forward earnings growth, at the 30th percentile, is the factor the Street is watching: bookings trajectory into year-end will determine whether that score improves.
The CEO selling, documented in detail in the September 30 note, has continued. August Troendle sold around 21,966 shares on September 30 at $625.47 and 26,701 shares the day before at $621.02. Total open-market sales since September 22 now represent a substantial accumulation of discretionary transactions. None were under a pre-arranged 10b5-1 plan. The institutional table adds a layer: Troendle's reported Schedule 13D/A stake has slipped from 20.0% to 19.1%, as disclosed in his September 28 amendment. He remains on the activist register under a 13D filing, meaning his intent is characterised as active rather than passive. The standard caveat applies: 13D/G positions are event-driven disclosures around the 5% threshold, and stakes are as last disclosed. Separately, T. Rowe Price stands out as the most notable institutional mover, adding 1.78 million shares in the period ending September 30, bringing its reported holding to 7.4% of shares outstanding.
The lending market adds little drama. Availability is extremely loose at over 4,100%, meaning shares to borrow vastly outnumber those already borrowed. Cost to borrow has fallen 25% over the past week to 0.26%, a level that signals no borrow pressure at all. Short interest at 5.9% of the free float has been essentially flat for a month, oscillating in a tight band around 1.66 million shares. The ORTEX short score, at 47.9, is near the midpoint and drifting slightly lower. Options positioning is elevated but unremarkable: the put/call ratio of 2.74 is marginally above its 20-day average of 2.67, a z-score of just 0.26, well within normal range. None of this points to any meaningful institutional short conviction ahead of the print.
Wikipedia views for Medpace are running well above their recent history, with a retail attention z-score of 2.86 against the company's own prior 90 days, the highest reading in the tracked window. That reflects the earnings proximity and the profile of the CEO selling, not a revenue signal. The alt-data suite carries no measured leading indicators for Medpace's reported financials, so the attention reading is colour rather than a read on the quarter.
The most direct comparables moved with MEDP on the week: TMO fell 3.4% and IQV dropped 3.3%, while CRL bucked the group with a 3% gain. The sector-wide softness means Medpace's weekly slide was not idiosyncratic.
With twelve days to the October 19 print, the key tension is whether bookings guidance for the second half of 2026 confirms the trajectory management signalled in July, or whether cancellation rates complicate the picture that now-upgraded analysts have baked in.
See the live data behind this article on ORTEX.
Open MEDP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
